The Summary
In a 16-week, double-blind randomized clinical trial, researchers evaluated whether oral semaglutide could improve motivation in 72 adults with major depressive disorder and a BMI of 25 or higher. Using the Effort-Expenditure for Rewards Task, participants on semaglutide showed an increased willingness to exert physical effort for monetary rewards compared to those on a placebo. Computational modeling revealed that semaglutide reduced effort discounting—essentially lowering the perceived cost of physical effort—while maintaining the same sensitivity to reward probability.
Why this is interesting
For years, GLP-1 drugs were viewed strictly as metabolic tools. This study reveals they can directly target the brain's reward circuitry to counter anhedonia—the inability to find motivation, which is a notoriously hard-to-treat symptom of depression. By making tasks feel less exhausting, semaglutide could offer a dual-benefit therapeutic pathway for patients struggling with both metabolic and mental health issues. If these findings hold, they could redefine how we treat motivational deficits across a range of neuropsychiatric conditions.